VYNE Therapeutics Inc.

VYNE Therapeutics Inc. (VYNE) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating surface-level stability in this window. However, absence of near-term events does not eliminate underlying risk; the full $49 Report extends analysis to 12 months of SEC filings, adds a quantified dilution risk score, maps financing history and capital structure, and identifies AI-flagged risk signals that may not yet surface as formal disclosures. The full $49 Report adds dilution trajectory, debt-to-equity trends, and forward guidance on refinancing pressure.